GLSI — Greenwich Lifesciences Share News
0.000.00%
Last trade - 00:00- $235.29m
- $226.42m
Greenwich Lifesciences Inc reports results for the quarter ended in December - Earnings Summary
Greenwich Lifesciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Greenwich Lifesciences Inc expected to post a loss of 20 cents a share - Earnings Preview
Brief: Greenwich Lifesciences Extends Lock-Up Of Directors And Officers To June 30, 2025
Brief: Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand Into Five European Countries
Greenwich LifeSciences up on positive DSMB feedback for cancer study
Brief: Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01
Brief: Greenwich Lifesciences Extends Lock-Up Of Directors And Officers
Brief: Greenwich Lifesciences Confirms FDA Reviewed Co's Mid-Stage Clinical Data Before The Commencement Of The Flamingo-01 Clinical Trial
Brief: Greenwich Lifesciences Says Does Not Hold Cash Deposits Or Securities At Silicon Valley Bank
Brief: Greenwich Lifesciences Extends Lock-Up Of Directors & Officers To End Of 2023
Brief: Greenwich LifeSciences Provides Updates On Flamingo-01 Phase III Clinical Trial
Brief: Greenwich LifeSciences Provides Financing Strategy & Corporate Update
U.S. STOCKS ON THE MOVE-Jiuzi Holdings Inc, Apple Inc, Cohu Inc
U.S. STOCKS ON THE MOVE-American Express Co, HyreCar Inc, Lordstown Motors Corp
U.S. STOCKS ON THE MOVE-Canoo Inc, PepsiCo Inc, Novo Integrated Sciences Inc
Brief: Greenwich Lifesciences Says May Offer, Sell Shares Of Common Stock Of Up To $100 Mln From Time To Time Through Jefferies
Brief: Greenwich Lifesciences Announces Removal Of Clinical Hold Permitting Phase III Clinical Trial To Proceed
Greenwich LifeSciences up as FDA removes clinical hold on cancer drug trial